How to evaluate the risk-benefit ratio of the low-dose hormone replacement therapy?

Journal of Steroid Biochemistry and Molecular Biology

Volumn 102, Issue 1-5 SPEC. ISS., 2006, Pages 256-260

  Rozenbaum, Henri ^a  

^a NONE   (France)

Author keywords

Bone mineral density; Breast cancer; Cardiovascular risk; Climacteric complaints; Critical window; Low dose HRT; Micronized progesterone; Transdermal estrogens; Venous thromboembolism

Indexed keywords

CLINICAL TRIALS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MENOPAUSE; RISK ASSESSMENT;

EID: 33751011044     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.09.013     Document Type: Article

References (33)

1. Writing Group For The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. Walsh B.W., Spiegelman D., Morrisey M., and Sacks F.M. Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with oral estradiol. J. Clin. Endocrinol. Metab. 84 (1999) 985-989
3. Schenkel L., Barlier D., Gay C., and Gschwind T. Substitution estrogénique par système transdermique. Rev. Fr. Gynécol. Obst. 83 (1988) 453-458
4. Heikkinennen J.E., Vaheri R.T., Ahomäki S.M., Kainulainen P.M.T., Viitanen A.T., and Timonen U.M. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am. J. Obstet. Gynecol. 182 (2000) 560-567
5. Utian W.H., Burry K.A., Archer D.F., Gallagher J.C., et al., The Esclim Study Group. Efficacy and safety of low, standard and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am. J. Obstet. Gynecol. 181 (1999) 71-79
6. Peeyananjarassri K., and Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 8 (2005) 13-23
7. Ettinger B. Unopposed ultra-low-dose estradiol: a new approach to osteoporosis prevention. Suppl. J. Fam. Practice (2004) S17-S19
8. Bellantoni M.F., Harman S.M., Cullins V.E., Engelhardt S.M., and Blackman M.R. Transdermal estradiol with oral progestin: biological and clinical effects in younger and older postmenopausal women. J. Gerontol. 46 6 (1991) M216-M222
9. Archer D.F., Dorin M., Lewis V., Schneider D.L., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxy-progesterone acetate on endometrial bleeding. Fertil. Steril. 75 (2001) 1080-1087
10. Gambacciani M., Ciaponi M., Cappagli B., and Genazzani A.R. Effects of low-dose continuous combined conjugated estrogens and medroxy-progesterone acetate on menopausal symptoms, body weight, bone density, and metabolism ins postmenopausal women. Am. J. Obstet. Gynecol. 185 (2001) 1180-1185
11. Dupont W.D., and Page D.L. Menopausal estrogen replacement therapy and breast cancer. Arch. Intern. Med. 151 (1991) 67-72
12. Collaborative Group On Hormonal Factors In Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350 (1997) 1047-1059
13. Chlebowski R.T., Hendrix S.L., Stefanick M.L., Gass M., Lane D., Rodabough R.J., et al., For the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The women's health initiative randomized trial. JAMA 289 (2003) 3243-3253
14. The Endogenous Hormones And Breast Cancer Collaborative. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 94 (2002) 606-616
15. Zeleniuch-Jacquotte A., Shore R.E., Koenig K.L., Akhmedkhanov A., Afanasyeva Y., Kato I., Kim M.Y., Rinaldi S., Kaaks R., and Toniolo P. Postmenopausal levels of estrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study British. J. Cancer 90 (2004) 153-159
16. Cummings S.R., Duong T., Kenyon E., Cauley J.A., Whitehead M., Krueger K.A., and For the Multiple Outcomes of Raloxifene Evaluation (More) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifen. JAMA 287 (2002) 216-220
17. Christodoulakos G.E., Lambrinoudaki I.V., Vourtsi A.D., Vlachou S., Creatsa M., Panoulis P.C., and Botsis D. The effect of low dose hormone therapy on mammographic breast density. Maturitas 54 (2006) 78-85
18. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., Trevisan M., Black H.R., Heckbert S.R., Detrano R., Strickland O.L., Wong N.D., Crouse J.R., Stein E., Cushman M., and For the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. Med. 349 (2003) 523-534
19. Hsia J., Langer R.D., Manson J.E., Kuller L., Johnson K.C., Hendrix S.L., Pettinger M., Heckbert S.R., Greep N., Crawford S., Eaton Ch B., Kostis J.B., Caralis P., Prentice R., and For the Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Arch. Intern. Med. 166 (2006) 357-365
20. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Women's Health 15 (2006) 35-44
21. Lobo R.A., Bush T., Carr B.R., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxy-progesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil. Steril. 76 (2001) 13-24
22. Wakatsuki A., Okatani Y., Ikenoue N., Shinohara K., Watanabe K., and Fukaya T. Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 108 (2003) 808-813
23. Li C., Samsioe G., Borgfeldt C., Bendahl P.O., Wilawan K., and Aberg A. Low-dose hormone therapy and carbohydrate metabolism. Fertil. Steril. 79 (2003) 550-555
24. Lindheim S.R., Presser S.C., Ditkoff E.C., Vijod M.A., Stanczyk F.Z., and Lobo R.A. A possible bimodal effect of estrogen on insulin sensivity in postmenopausal women and the attenuating effect of added progestin. Fertil. Steril. 60 (1993) 664-667
25. Mercuro G., Vitale C., Fini M., Zoncu S., Leonardo F., and Rosano G. Lipid profiles and endotheliaal function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial. Int. J. Cardiol. 89 (2003) 257-265
26. Clarkson T.B., and Appt S.E. Controversies about HRT-lessons from monkey models. Maturitas 51 (2005) 64-74
27. Hodis H.N., Mack W.J., Azn S.P., Lobo R.A., Shoupe D., Mahrer P.R., Faxon D.P., Cashin-Hemphill L., Sanmarco M.E., French W.J., Shook T.L., Gaarder T.D., Mehra A.O., Rabbani R., Sevanian A., Shil A.B., Torres M., Vogelbach H., Selzer R.H., and For the Women's Estrogen-progestin Lipid-lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. Med. 349 (2003) 535-545
28. Hodis H.N., Mack W.J., Lobo R.A., Shoupe D., Sevanian A., Mahrer P.R., et al., For the Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Int. Med. 135 (2001) 939-953
29. Salpeter S.R., Walsh J.M.E., Greyber E., and Salpeter E.E. Brief report: coronary heart disease events associated with hormone therapy in younger and older women-a meta analysis. J. Gen. Intern. Med. 21 (2006) 363-366
30. Zandi P.P., Carlson M.C., Plassman B.L., et al., For the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the cache county study. JAMA 288 (2002) 2123-2129
31. e world congress on the menopause. Climacteric 8 Suppl. 2 (2005) 236
32. e world congress on the menopause. Climacteric 8 Suppl. 2 (2005) 235
33. Swift J.A., Conway P., and Purdie D.W. A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus. Curr. Med. Res. Opin. 21 (2005) 2051-2061